BRISBANE, Calif.--(BUSINESS WIRE)--Jun. 8, 2017--
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that CFO Eric Bjerkholt will present a company overview at the
Goldman Sachs 38th Annual Global Healthcare conference in
Rancho Palos Verdes, California, on Thursday, June 15, at 10:00 a.m.
The live webcast of the presentation will be accessible on the Events
page under the Investor Relations section of the Aimmune website at www.aimmune.com.
The replay of the webcast will be available for at least 30 days
following the webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™)
approach is intended to achieve meaningful levels of protection by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first investigational product using CODIT™, AR101 for the
treatment of peanut allergy, has received the FDA’s Breakthrough Therapy
Designation for the desensitization of peanut-allergic patients 4-17
years of age and is currently being evaluated in Phase 3 clinical trials
in ages 4-55. AR101 is a characterized, regulated, oral biological drug
product containing the protein profile found in peanuts. For more
information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170608005472/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.